Shreyas Kalantri, Hematology and Oncology Fellow at University of Louisville, shared on X:
“85% planned it. Only 47.5% reported it.
In our new study of 80 phase III GUOnc trials, QoL endpoints were frequently prespecified but often went unreported.
Among trials that prespecified QoL, reporting was significantly more common when the primary endpoint was positive: 71% vs 31%. Our findings highlight the need for consistent, transparent reporting of patient-centered outcomes – regardless of trial outcome.
Now published open access in JCO Oncology Advances.”
Title: Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials
Authors: Shreyas Kalantri, Shiva Balasubramanian, Jincong Q. Freeman, Tyler Jones, Priyanka Sheth, Srinidhi Karthik, Jason Chesney, Rohit Kumar
To which Walter Stadler, Chief Clinical Officer, City of Hope Chicago, added:
“QOL endpoints are critical.
But name studies in which the usual cancer endpoints were negative but QOL was positive!
Unless we create better ways to measure QOL we will continue to have a problem.
With multiple sequential effective (sometimes toxic) therapies this is critical.”
Other articles about Genitourinary Cancer on OncoDaily.